Analyst Sentiment on Alumis (ALMS) Remains Strong Following Q1 Results and Envudeucitinib Pipeline Advancements

Alumis Inc. (NASDAQ: ALMS) continues to attract positive analyst sentiment following its first-quarter results and progress in the envudeucitinib pipeline, with three major price target raises from Chardan, Wells Fargo, and Guggenheim.

By Faheem Tahir Fri, May 29, 2026 at 1:31 PM GMT+3 2 min read · Yahoo Finance · May 29, 2026, 10:31 UTC

Tickers: $ALMS

Topics: analyst ratings biotech clinical trials pharmaceuticals

Read the full article at Yahoo Finance

More World news

Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC
Pelagos Insurance Reports Q3 2026 Earnings with Increased Gross Premiums Written Motley Fool · November 12, 2026, 18:11 UTC
Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC
NYSE Gains $500 Billion in Market Capitalization via Nine Major Listing Transfers PR Newswire · November 12, 2026, 18:05 UTC
PenFed Foundation Grants $25,000 to Northern Virginia Vietnam Veterans Foundation PR Newswire · November 12, 2026, 18:06 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC